ImmunoPrecise Antibodies Ltd (IPA)
0.4599
-0.02
(-4.19%)
USD |
NASDAQ |
Nov 14, 16:00
0.50
+0.04
(+8.72%)
After-Hours: 20:00
ImmunoPrecise Antibodies Gross Profit Margin (Quarterly): 44.77% for July 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2024 | 44.77% |
| April 30, 2024 | 48.12% |
| January 31, 2024 | 51.39% |
| October 31, 2023 | 48.03% |
| July 31, 2023 | 49.14% |
| April 30, 2023 | 59.44% |
| January 31, 2023 | 57.32% |
| October 31, 2022 | 53.61% |
| July 31, 2022 | 52.87% |
| April 30, 2022 | 63.29% |
| January 31, 2022 | 53.71% |
| October 31, 2021 | 54.53% |
| July 31, 2021 | 54.62% |
| April 30, 2021 | 56.94% |
| January 31, 2021 | 78.89% |
| October 31, 2020 | 58.65% |
| Date | Value |
|---|---|
| July 31, 2020 | 64.01% |
| April 30, 2020 | 46.90% |
| January 31, 2020 | 55.12% |
| October 31, 2019 | 78.74% |
| July 31, 2019 | 50.68% |
| April 30, 2019 | 21.62% |
| January 31, 2019 | 58.17% |
| October 31, 2018 | 51.59% |
| July 31, 2018 | 54.58% |
| April 30, 2018 | 40.64% |
| January 31, 2018 | 57.40% |
| October 31, 2017 | 40.51% |
| July 31, 2017 | 7.89% |
| April 30, 2017 | 93.34% |
| January 31, 2017 | 24.43% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
44.77%
Minimum
Jul 2024
78.89%
Maximum
Jan 2021
55.33%
Average
54.53%
Median
Oct 2021
Gross Profit Margin (Quarterly) Benchmarks
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -61.97% |
| Return on Assets | -39.40% |
| Return on Invested Capital | -61.27% |
| Profit Margin (Quarterly) | -75.98% |
| Operating Margin (Quarterly) | -87.92% |
| Return on Net Operating Assets | -39.45% |